Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | FOS | P01100 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959285 | 0.87 | FOS (0.71) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL8828295 | 0.84 | CA2 (0.60) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL30559576 | 0.84 | CA2 (0.60) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL1026086 | 0.84 | CA2 (0.60) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL1023836 | 0.84 | CA2 (0.60) | LDHAALOX15ALOX12CA2KDM1A | |
| Hydrochloric Acid SCHEMBL23524379 | 0.83 | CA2 (0.58) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL11080689 | 0.83 | LDHA (0.54) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL13748410 | 0.81 | SIGMAR1 (0.54) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL9119369 | 0.81 | KMT2A (0.70) | LDHAALOX15ALOX12CA2KDM1A | |
| SCHEMBL9119354 | 0.81 | KMT2A (0.70) | LDHAALOX15ALOX12CA2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | claimed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | claimed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | claimed |
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | disclosed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | LDHA 3208/4885ALOX15 3845/4885ALOX12 3814/4885 |
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | LDHA 3199/4885ALOX15 3665/4885ALOX12 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.